As an approved second-line tyrosine kinase inhibitor (TKI) for HCC [29], regorafenib exerts its effects by inhibiting kinases such as RAF and VEGFR [30] and is the only therapy with survival benefits after sorafenib progression [31]. This evidence concerns the gene KDR and hepatocellular carcinoma.